Overview
This real-world study examined what happens after patients with metastatic castration-resistant prostate cancer (mCRPC) receive lutetium-177 vipivotide tetraxetan (Lu177), a newer treatment for patients with mCRPC. Using data from over 740 patients treated with Lu177 across U.S. oncology practices, researchers found that 161 patients (22%) received additional treatment after Lu177.
The results revealed heterogeneity in approaches to treatment of patients post- Lu177., with over 40 different treatment combinations used. About half of these patients received chemotherapy-based treatments, with cabazitaxel monotherapy being most common (19%), followed by cabazitaxel with carboplatin (12%). Notably, the median overall survival after Lu177 was only 8.0 months overall—13.5 months for patients not previously treated with taxane chemotherapy and 6.8 months for those who had previously received a taxane. Patients with poor performance status and shorter Lu177 treatment duration experienced worse outcomes.
Why this matters
This study reveals a critical unmet need in mCRPC management. The short survival times and highly variable treatment approaches after Lu177 highlight the urgent need for more effective therapeutic options. These real-world findings will help oncologists understand post-Lu177 outcomes and inform the development of improved treatment strategies to better serve patients withCRPC following Lu177 treatment.